MON-691 Association of Serum Level of Omentin-1, Hs-CRP and Atherosclerosis in Patients with Type 2 Diabetes

Abstract

Omentin-1 has been identified as an interesting novel adipokine that may modulate the action of insulin. Serum omentin-1 levels were associated with endothelial dysfunction and cardiovascular diseases, which highly contribute to morbidity and mortality of patients with diabetes, however its exact biological function is still unclear. The aim of this study was to assess the level of circulating plasma Omentin-1 level in patients with type 2 diabetes compared to control subjects, and to investigate the relationship of circulating Omentin-1levels with HOMA, BMI, lipid profile, epicardial fat, visceral fat and subcutaneous fat in early stages of atherosclerosis measured by carotid intima media thickness (CIMT). This is a cross-sectional observational study which included 45 patients with type 2 DM (not previously diagnosed as ACVD patients) and 30 (age and sex)-matched healthy control subjects. Patients with a history of recent acute infection, malignancy, metabolic or endocrinal diseases, cardiac failure, renal and hepatic impairment were excluded. Participants were subjected to measurement of FPG, HbA1c, lipid profile, calculation of HOMA2, hs CRP, serum omentin-1, CIMT, estimation of visceral, epicardial and subcutaneous fat through CAT scanning. There was no statistically significant difference between both groups in the mean circulating omentin-1 level, a mean of (793.86 ± 195.81) ng/ml in type 2 diabetes Vs (804.93 ± 205.76) ng/ml in the control group,(p=0.654). However, there was a highly statistically significant difference in hs-CRP between both groups, mean hs CRP is (4.29 ± 4.87 mg/l) vs (0.92 ± 0.53 mg/l) respectively. There was a statistically significant negative correlation between omentin-1 and hs CRP (r= -0.278, p= 0.016).There were no statistically significant correlations between omentin-1 with BMI, HbA1c, HOMA, lipid profile or adiposity. These findings may denote the anti-inflammatory effects of omentin-1 which maybe unrelated to insulin resistance and dyslipidemia. Further studies are required to confirm the cardioprotective role of omentin-1 in patients with type 2 diabetes, focusing on its local anti-inflammatory role.Nothing to disclose: MA, NA, NKNo Sources of Research Support